Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Soluble P-Selectin Levels in Patients with Sickle Cell Disease Reflect Platelets' Activation Rather Than Endothelial Dysfunction

Ersi Voskaridou, Mantzou Aimilia, PhD, Pagona Flevari, MD, Maria Dimopoulou, MD, Veroniki Komninaka, MD, Konstantina Repa, MD, Ioannis Papassotiriou, PhD

Blood (2019) 134 (Supplement_1): 4829.

https://doi.org/10.1182/blood-2019-122524

Published: 2019

Journal Articles

Non Invasive Evaluation of Bone Marrow Activity in Patients with Sickle Cell Disease: Correlation with Disease Features, Genotype, Markers of Erythropoiesis, Iron Metabolism and Hydroxyurea Treatment

Ioannis Papassotiriou, PhD, Pagona Flevari, MD, Christos Poziopoulos, MD, Sofia Zaliou, PhD, Vasilis Tsaousis, PhD, Katerina Larissi, MD, Maria Dimopoulou, MD, Veroniki Komninaka, MD, Marianna Politou, MD, Evangelos Terpos, MD, Ersi Voskaridou

Blood (2019) 134 (Supplement_1): 4821.

https://doi.org/10.1182/blood-2019-121622

Published: 2019

Journal Articles

The Growth Differentiation Factor-15 Levels Are Increased in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia, Correlate with Hepcidin-25/Ferritin Molar Ratio and with Markers of Hemolysis, Endothelial Dysfunction and Angiogenesis

Ioannis Papassotiriou, PhD, Katerina Larrisi, MD, Alexandra Margeli, PhD, Dimitrios Christoulas, Maria Dimopoulou, MD, Vaughn Ostland, PhD, Christos Poziopoulos, Mark Westerman, PhD, Marianna Politou, MD, Ersi Voskaridou, MD, Evangelos Terpos, MD PhD

Blood (2016) 128 (22): 3646.

https://doi.org/10.1182/blood.V128.22.3646.3646

Published: 2016

Journal Articles

Targeted Metabolomic Profiles Are Strongly Correlated With Metabolic Alterations In Patients With Sickle Cell/Beta Thalassemia Disease

Ioannis Papassotiriou, Fottes Panetsos, PhD, Theodora Livadara, MSc, Maria Dimopoulou, MD, Andreas Tzivaras, BSc, Ersi Voskaridou, MD

Blood (2013) 122 (21): 4675.

https://doi.org/10.1182/blood.V122.21.4675.4675

Published: 2013

Journal Articles

T Cell Depletion with Alemtuzumab Is Associated with a High Incidence of EBV Viraemia but Low Risk of PTLD Following Allogeneic Stem Cell Transplantation

Ben Carpenter, MD, Maria Dimopoulou, MD, Nilusha Manji, Tanzina Haque, MD, Claire Atkinson, MD, Sarah Grace, Stephen Mackinnon, MD, Ronjon Chakraverty, MD

Blood (2008) 112 (11): 1177.

https://doi.org/10.1182/blood.V112.11.1177.1177

Published: 2008

Journal Articles

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Ronjon Chakraverty, MD, Maria Dimopoulou, MD, Julie Glanville, MD, Kirsty Thomson, MD, Karl Peggs, MD, Donald Milligan, MD, Gordon Cook, MD, Graham Jackson, MD, Anne Parker, MD, Ann Hunter, MD, Nigel Russell, MD, Rachel Pearce, Stephen Mackinnon, MD

Blood (2006) 108 (11): 2901.

https://doi.org/10.1182/blood.V108.11.2901.2901

Published: 2006

NARROW

Soluble P-Selectin Levels in Patients with Sickle Cell Disease Reflect Platelets' Activation Rather Than Endothelial Dysfunction

Non Invasive Evaluation of Bone Marrow Activity in Patients with Sickle Cell Disease: Correlation with Disease Features, Genotype, Markers of Erythropoiesis, Iron Metabolism and Hydroxyurea Treatment

The Growth Differentiation Factor-15 Levels Are Increased in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia, Correlate with Hepcidin-25/Ferritin Molar Ratio and with Markers of Hemolysis, Endothelial Dysfunction and Angiogenesis

Targeted Metabolomic Profiles Are Strongly Correlated With Metabolic Alterations In Patients With Sickle Cell/Beta Thalassemia Disease

T Cell Depletion with Alemtuzumab Is Associated with a High Incidence of EBV Viraemia but Low Risk of PTLD Following Allogeneic Stem Cell Transplantation

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Email alerts

ASH Publications

American Society of Hematology

Soluble P-Selectin Levels in Patients with Sickle Cell Disease Reflect Platelets' Activation Rather Than Endothelial Dysfunction

Non Invasive Evaluation of Bone Marrow Activity in Patients with Sickle Cell Disease: Correlation with Disease Features, Genotype, Markers of Erythropoiesis, Iron Metabolism and Hydroxyurea Treatment

The Growth Differentiation Factor-15 Levels Are Increased in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia, Correlate with Hepcidin-25/Ferritin Molar Ratio and with Markers of Hemolysis, Endothelial Dysfunction and Angiogenesis

Targeted Metabolomic Profiles Are Strongly Correlated With Metabolic Alterations In Patients With Sickle Cell/Beta Thalassemia Disease

T Cell Depletion with Alemtuzumab Is Associated with a High Incidence of EBV Viraemia but Low Risk of PTLD Following Allogeneic Stem Cell Transplantation

De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only